Last Updated: 16 Sep 2024
Executive Summary
Sunshine Biopharma Inc. (SBFM) is a pharmaceutical company focused on developing anticancer drugs. The company has a market capitalization of $3.43 million and trades on the NASDAQ exchange. The stock price is currently $2.82, which is below the analyst target price of $300. The company has a strong buy rating from one analyst.
Company Overview
Sunshine Biopharma is headquartered in Pointe-Claire, Canada. The company was founded in 2003 and has a team of experienced scientists and researchers. The company's lead product candidate is Adva-27a, a small molecule drug that is being developed for the treatment of metastatic breast cancer. Adva-27a has shown promising results in preclinical studies and is currently in Phase II clinical trials.
Fundamental Analysis
Sunshine Biopharma's financial performance has been mixed in recent years. The company has reported losses in each of the past three years. However, the company's revenue has grown in each of the past two years. In 2023, the company reported revenue of $30.48 million, up from $28.69 million in 2022. The company's net loss was $44.01 million in 2023, compared to a net loss of $47.76 million in 2022.
The company's balance sheet is strong. As of December 31, 2023, the company had cash and cash equivalents of $44.1 million and total assets of $65.2 million. The company's long-term debt was $10.0 million.
Technical Analysis
The technical analysis of Sunshine Biopharma's stock price shows that the stock is in a downtrend. The stock price has been below its 50-day and 200-day moving averages for the past several months. The stock price is also below its 52-week low of $2.42.
Short Term Outlook
The short-term outlook for Sunshine Biopharma's stock is negative. The stock price is in a downtrend and is below its key moving averages. The stock price is also below its 52-week low.
Long Term Outlook
The long-term outlook for Sunshine Biopharma's stock is mixed. The company has a strong pipeline of drug candidates and has shown promising results in preclinical studies. However, the company has reported losses in each of the past three years and its stock price is in a downtrend.
Analyst Recommendations
One analyst has a strong buy rating on Sunshine Biopharma's stock. The analyst believes that the company's pipeline of drug candidates has the potential to generate significant revenue in the future. The analyst also believes that the company's stock price is undervalued.
